Pinnacle Wealth Planning Services’s Cytokinetics CYTK Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.7K	Hold	713	–	–	0.01%	1141
2026 Q1	$47K	Sell	713 -23	-3%	-$1.46K	﹤0.01%	1242
2025 Q4	$46.8K	Buy	+736	New	+$45.8K	﹤0.01%	1240
2024 Q2	–	Sell	-3,015	Closed	-$211K	–	520
2024 Q1	$211K	Hold	3,015	–	–	0.03%	410
2023 Q4	$252K	Buy	+3,015	New	+$109K	0.04%	321
2021 Q1	–	Sell	-95	Closed	-$2K	–	745
2020 Q4	$2K	Buy	+95	New	+$1.74K	﹤0.01%	1917

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pinnacle Wealth Planning Services's CYTK Position: Q2 2026 in Review

Pinnacle Wealth Planning Services held its Cytokinetics (CYTK) position steady in Q2 2026 at 713 shares worth $60.7K. The position accounts for 0.01% of the portfolio, ranked #1141.

Pinnacle Wealth Planning Services first reported a position in CYTK in Q4 2020 and has held it in 6 quarters since. The position peaked at $252K in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Pinnacle Wealth Planning Services held 713 shares of Cytokinetics worth $60.7K as of Q2 2026.
Pinnacle Wealth Planning Services left its Cytokinetics share count unchanged in Q2 2026.
Cytokinetics made up 0.01% of Pinnacle Wealth Planning Services's portfolio in Q2 2026, its #1141 holding.
Pinnacle Wealth Planning Services first reported a position in Cytokinetics in Q4 2020 and has held it in 6 quarters since.
Pinnacle Wealth Planning Services's Cytokinetics position peaked at $252K in Q4 2023.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q2 2026, filed 7 Aug 2026.